– IDHIFA® (enasidenib) Granted Approval from FDA as First Targeted Therapy for Patients with ...
Highland Park Medical Director Dr. Edward L. Marut and Industry-Leading Physicians Dr. Brian R. ...
—More than 20 percent of adult CABP patients failed initial antibiotic monotherapy, including approximately ...
